Sentences with phrase «t cell therapy»

Re-directed Autologous T cell Therapy for drug resistant or refractory CD20 + B cell lymphoma Overview: In this approach, immune cells (known as T cells) are taken from the peripheral blood, genetically modified in the laboratory to express a receptor that recognizes B cells, and then expanded to produce large numbers of tumor specific T cells outside -LSB-...]

As part of the SFB - TR36 Transregional Collaborative Research Center and other funding programs (Einstein Visiting Fellowship, BIH, the DKTK, and German Cancer Aid), we have been addressing the fundamental principles and clinical applications of T cell therapy.

Tags: checkpoint inhibitors, Clinical Research, immunotherapy, Lung Cancer, McGarry Houghton, Ovarian Cancer, pembrolizumab, Philip D Greenberg, solid tumors, T cell, t cell therapy, Transplant and Immunotherapy

In the case of CAR T cell therapy — which re-educates immune cells to attack blood cancers and other diseases — dozens of researchers and physicians throughout City of Hope contribute to its momentum.

Our success with CAR - T cell therapy is all thanks to the help we've received from our partners, researchers, philanthropists, and fellow cancer visionaries.

One way that we're doing this is through an immunotherapy treatment option called CAR - T cell therapy.

Carl June, MD, is one of the pioneers of immunotherapy research, and he leads the team responsible for the historic CAR - T cell therapy FDA approval.

Carl June, MD, has been named one of TIME's 100 most influential people for his pioneering work in the development of CAR - T cell therapy at Penn Medicine.

In addition to CAR - T cell therapy, we focus on other types of immunotherapy research, such as vaccine therapy and checkpoint inhibitors.

CAR - T cell therapy is a specific form of adoptive T cell transfer in which T cells are removed from the patient, genetically engineered in the lab to recognize a cancer antigen, expanded to billions of copies, and then returned to the patient.

Another major hurdle of contemporary immunotherapy concerns finding appropriate targets for CAR - T cell therapy.

One specific form of this approach, called chimeric antigen receptor (CAR) T cell therapy, has been shown in early clinical trials to be particularly effective at treating lymphoma.

However, at least 30 % of patients will relapse following CAR T cell therapy due to selection of leukemic cells that lack CD19.

Unlike ongoing CAR T cell therapy trials, Sadelain constructed a CAR treatment where the primary route of administration is via the intrapleural membranes around the lungs, as opposed to the customary intraveinous infusion.

New research into CAR - T cell therapy has revealed crucial mechanisms that could help the immunotherapy technique, which is currently only effective against blood cancers, be adapted for the treatment of brain tumors and other forms of solid cancers.

Endogenous T cell therapy utilizes naturally - occurring antigen - specific T cells isolated from peripheral blood to treat solid tumor malignancies.

Riewaldt J, Düber S, Boernert M, Krey M, Dembinski M, Weiss S, Garbe AI, Kretschmer K. Severe developmental B lymphopoietic defects in Foxp3 - deficient mice are refractory to adoptive regulatory T cell therapy.

Passive immunization, herein referred to as adoptive T cell therapy, is the transfusion of autologous or allogeneic T cells into tumor - bearing hosts, i.e., patients.

He continues to investigate and optimize CAR T cell therapy, to make it more effective not only for blood cancers, but also to help patients with other types of cancer.

because the outcomes with CAR - T cell therapy were not very encouraging.

Locally Produced Dual Targeted anti-CD19 / anti-CD20 CAR - T cell Therapy for Patients with Relapsed, Refractory NHL Nirav Shah, MD, MS, Medical College of Wisconsin, United States

It is also the first time a Roswell Park team has produced a genetically engineered T cell therapy in - house.

The landscape of CAR - T cell therapy.

Learn about the process behind Penn's CAR - T cell therapy, the first - ever cancer treatment that genetically alters a patient's own immune cells to target and destroy cancer cells.

Ultimately, the team hopes to combine their armor penetrating - approach with adoptive T cell therapy, as well as standard chemo.

New blood cancer breakthroughs — including several involving CAR T cell therapy — were announced by City of Hope physicians at the American Society of Hematology (ASH) annual meeting in Atlanta.

Chimeric Antigen Receptor - T Cell Therapy: Practical Considerations for Implementation in Europe

-- Poseida Therapeutics released very early data from a Phase 1 study of its CAR - T cell therapy for multiple myeloma.

CRI: Later this year in October you're going to receive CRI's Coley Award along with Michel Sadelain for your work in developing CAR T cell therapy.

But there's reason for optimism - recent advances in screening and treatment, such as CAR T cell therapy, mean patient outcomes and quality of life are continuing to improve.

Newer cancer treatments, like adoptive T cell therapy, use a variety of ways to strengthen T cells for the fight and He says the mouse receptor genes could be another way to do that.

We've found innovative ways to treat challenging diseases (the U.S. Food and Drug Administration's approval of CAR - T cell therapy for certain blood cancers is our No. 8 story).

Reporting in the Journal of Clinical Investigation Insights, a team led by senior author Andrea Facciabene, PhD, a research assistant professor of Radiation Oncology and Obstetrics / Gynecology, found that the effectiveness of adoptive T cell therapy (ACT) in mice with cancer is significantly affected by differences in the natural makeup of gut bacteria and treatment with antibiotics.

The treatment is a form of so - called CAR - T cell therapy.

«Promising T cell therapy to protect from infections after transplant.»

«CAR T cell therapy can now target solid tumors: Mouse study.»

Chimeric antigen receptor (CAR) T cell therapy, which edits a cancer patient's T cells to recognize their tumors, has successfully helped patients with aggressive blood cancers but has yet to show the ability to treat solid tumors.

In recent clinical trials, CAR T cell therapy has dramatically improved the outcomes of blood cancer patients with advanced, otherwise untreatable forms of leukemia and lymphoma.

If these preclinical studies are successful, the researchers plan to further develop their CAR T cell therapy and test its safety and efficacy for different types of metastatic cancer in upcoming clinical trials.

Over the past two years, investigators from the Perelman School of Medicine at the University of Pennsylvania have reported results from a human trial in GBM using chimeric antigen receptor (CAR) T cell therapy, through which patients» own T cells were engineered to track down and kill cancer cells that express a tumor - specific protein known as EGFRvIII.

The treatment with the engineered immune cells, called CAR - T cell therapy, may work even better if doctors transplant a subset of immune cells known as memory T cells, researchers reported February 14...

Adoptive T cell therapy, on the other hand, enlists the body's T cells to attack tumors.

That first year on the drug may provide an optimal window to collect T cells from patients and subsequently administer a potentially curative T cell therapy, the authors said.

CAR - T cell therapy is particularly exciting because it works well in people whose cancers haven't responded to other available treatments, says Renier Brentjens, an oncologist at Memorial Sloan Kettering Cancer Center in New York City.

FDA approves CAR - T cell therapy to treat adults with certain types of large B - cell lymphoma.

CANCER CRUSH In CAR - T cell therapy, a cancer treatment approved by the FDA this year for certain blood cancers, a patient's T cells (teal) are genetically modified to hunt down and kill cancer cells (blue).

For now, the treatments are approved for use only when other treatments have failed, but someday CAR - T cell therapy could be the first treatment doctors try, he says.

They then tried adoptive T cell therapy (ACT), in which T cells directed against a tumor are infused into a patient.

CAR - T cell therapy took the cancer world by storm in the summer of 2010.

Dr. Newman added that rival CAR T cell therapy developer Kite Pharma was still likelier to generate more revenue than Juno with KTE - C19, which last week completed patient enrollment in the Phase II portion of the ZUMA - 1 trial in patients with diffuse large B - cell lymphoma.